

## Editors

**B. Chankvetadze**, Molecular Recognition and Separation Science Laboratory, School of Chemistry, Tbilisi State University, 380028 Tbilisi, Georgia. *Submission address*: Sepaserve GmbH, Johann-Krane-Weg 42, 48149 Münster, Germany. E-mail: jpba\_bezhan@yahoo.com

**S. Görög**, Chemical Works of Gedeon Richter Ltd., P.O. Box 27, H-1475 Budapest 10, Hungary. E-mail: s.gorog@richter.hu

**J. Haginaka**, Faculty of Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyuban-cho, Nishinomiya 663-8179, Japan. E-mail: jpba@jpba@mukogawa-u.ac.jp

**R. Moaddel**, Baltimore, MD. 21224. USA. Tel: - +1-301-792-6579.

**S. Pinzauti**, Department of Pharmaceutical Sciences, University of Florence, Polo Scientifico, Via U. Schiff 6, 50019 Sesto Fiorentino, Italy. E-mail: pinz@unifi.it

## Editorial Advisory Board

**C. Barbas** (Madrid, Spain)

**M.G. Bartlett** (Athens, GA, USA)

**F. Bressolle** (Montpellier, France)

**P.S. Callery** (Morgantown, WV, USA)

**V. Cavrini** (Bologna, Italy)

**T.L. Cecil** (Rockville, MD, USA)

**A. Cifuentes** (Madrid, Spain)

**J. Crommen** (Liège, Belgium)

**S. Fanali** (Monterotondo Scalo, Italy)

**S. Furlanetto** (Florence, Italy)

**R. Gotti** (Bologna, Italy)

**U. Holzgrabe** (Würzburg, Germany)

**K. Kakehi** (Higashi-Osaka, Japan)

**R. Kaliszán** (Gdansk, Poland)

**I. Kanfer** (Grahamstown, South Africa)

**J.S. Kang** (Daejeon, South Korea)

**W. Lindner** (Vienna, Austria)

**H. Lingeman** (Amsterdam, The Netherlands)

**C.E. Lunte** (Lawrence, KS, USA)

**G. Markó-Varga** (Lund, Sweden)

**B.K. Matuszewski** (West Point, PA, USA)

**M.C.B.S.M. Montenegro** (Porto, Portugal)

**T. Nakagawa** (Kyoto, Japan)

**K. Nakashima** (Nagasaki, Japan)

**B. Noszál** (Budapest, Hungary)

**B.A. Olsen** (Indianapolis, IN, USA)

**K.W. Phinney** (Gaithersburg, MD, USA)

**R. Sandulescu** (Cluj-Napoca, Romania)

**K.E. Scriba** (Jena, Germany)

**K. Shimada** (Sendai, Japan)

**S. Singh** (S.A.S. Nagar, India)

**H. Ulrich** (São Paulo, Brazil)

**Y. van der Heyden** (Brussels, Belgium)

**J.-L. Veuthey** (Geneva, Switzerland)

**I.D. Wilson** (Macclesfield, UK)

**G. Xu** (Dalian, China)

## Aims and Scope

This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focussing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome. Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants. Papers dealing with the analytical aspects of traditional folk medicines are acceptable if the results are expected to attract the interest of readers also outside the area of origin. Bioanalytical papers (pharmacokinetic, bioequivalence, protein and DNA binding studies) are accepted if the focus is on innovative analytical methodology.

In determining the suitability of submitted articles for publication, particular scrutiny will be placed on the degree of novelty and significance of the research and the extent to which it adds to existing knowledge in pharmaceutical and biomedical analysis. In all submissions to the journal, authors must address the question of how their proposed methodology compares with previously reported methods. A substantial body of work cannot be fractionated into different shorter papers.

## Audience

Analytical scientists, management in the pharmaceutical industry, clinical chemistry laboratories, academic institutions, government agencies, biochemists, microbiology specialists, pharmaceutical formulation scientists.

## Author enquiries

For enquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage at <http://www.elsevier.com/locate/jpba>. You can track accepted articles at <http://www.elsevier.com/trackarticle> and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more.

Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.

## Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>

---